Targeting Hedgehog (Hh) Pathway for the Acute Myeloid Leukemia Treatment

被引：46
|
作者：
Terao, Toshiki [1 ,2 ]
Minami, Yosuke [1 ]
机构：
[1] Natl Canc Ctr Hosp East, Dept Hematol, Kashiwa, Chiba 2778577, Japan
[2] Kameda Med Ctr, Dept Internal Med, Div Hematol Oncol, Kamogawa 2968602, Japan
来源：
CELLS | 2019年 / 8卷 / 04期
关键词：
Hedgehog pathway; acute myeloid leukemia; AML; leukemic stem cell; glioma; Smoothened; glasdegib; sonidegib; STEM-CELLS; MYELODYSPLASTIC SYNDROME; GLASDEGIB PF-04449913; CLINICAL-IMPLICATIONS; PHASE IB; GLI; INHIBITOR; MUTATIONS; ACTIVATION; THERAPY;
D O I：
10.3390/cells8040312
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
The Hedgehog (Hh) pathway, containing the Patched (PTCH) and Smoothened (SMO) multitransmembrane proteins, is the main regulator of vertebrate embryonic development. A non-canonical Hh pathway was recently observed in numerous types of solid cancers and hematological malignancies. Although acute myeloid leukemia (AML) is a common and lethal myeloid malignancy, the chemotherapy for AML has not changed in the last three decades. The Hh pathway and other intracellular signaling pathways are important for the tumor cells' cycle or therapeutic resistance of AML cells. In this article, we will review the current trends in Hh pathway inhibitors for treating AML.
引用
收藏
页数：11
相关论文
共 50 条
  • [31] Targeting the hedgehog pathway in the treatment of breast cancer
    Steg, Adam
    Kwon, Yeon-Jin
    Johnson, Martin
    Frost, Andra
    CANCER RESEARCH, 2009, 69
  • [32] Targeting the hedgehog pathway to mitigate treatment resistance
    Chen, Yu-Jen
    Sims-Mourtada, Jennifer
    Izzo, Julie
    Chao, K. S. Clifford
    CELL CYCLE, 2007, 6 (15) : 1826 - 1830
  • [33] Targeting Mitochondrial Structure Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment
    Chen, Xufeng
    Glytsou, Christina
    Zhou, Hua
    Narang, Sonali
    Reyna, Denis E.
    Lopez, Andrea
    Sakellaropoulos, Theodore
    Gong, Yixiao
    Kloetgen, Andreas
    Yap, Yoon Sing
    Wang, Eric
    Gavathiotis, Evripidis
    Tsirigos, Aristotelis
    Tibes, Raoul
    Aifantis, Iannis
    CANCER DISCOVERY, 2019, 9 (07) : 890 - 909
  • [34] Targeting LSD1 for acute myeloid leukemia (AML) treatment
    Zhang, Shujing
    Liu, Menghan
    Yao, Yongfang
    Yu, Bin
    Liu, Hongmin
    PHARMACOLOGICAL RESEARCH, 2021, 164
  • [35] Targeting Innate and Adaptive Immune Responses for the Treatment of Acute Myeloid Leukemia
    Przespolewski, Amanda
    Portwood, Scott
    Den Haese, Jason
    Lewis, Demi
    Wang, Eunice S.
    BLOOD, 2016, 128 (22)
  • [36] Acute Myeloid Leukemia and the Wnt Pathway
    Eaves, Connie J.
    Humphries, R. Keith
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (24): : 2326 - 2327
  • [37] Glasdegib Hedgehog signaling inhibitor Treatment of myelodysplastic syndrome Treatment of chronic myelomonocytic leukemia Treatment of acute myeloid leukemia Treatment of myelofibrosis
    Gras, J.
    DRUGS OF THE FUTURE, 2017, 42 (05) : 265 - 274
  • [38] The BET bromodomain inhibitor ZEN-3365 targets the Hedgehog signaling pathway in acute myeloid leukemia
    Jasmin Wellbrock
    Lena Behrmann
    Jana Muschhammer
    Franziska Modemann
    Kais Khoury
    Franziska Brauneck
    Carsten Bokemeyer
    Eric Campeau
    Walter Fiedler
    Annals of Hematology, 2021, 100 : 2933 - 2941
  • [39] The BET bromodomain inhibitor ZEN-3365 targets the Hedgehog signaling pathway in acute myeloid leukemia
    Wellbrock, Jasmin
    Behrmann, Lena
    Muschhammer, Jana
    Modemann, Franziska
    Khoury, Kais
    Brauneck, Franziska
    Bokemeyer, Carsten
    Campeau, Eric
    Fiedler, Walter
    ANNALS OF HEMATOLOGY, 2021, 100 (12) : 2933 - 2941
  • [40] The Role of JAK Pathway Dysregulation in the Pathogenesis and Treatment of Acute Myeloid Leukemia
    Lee, Hun Ju
    Daver, Naval
    Kantarjian, Hagop M.
    Verstovsek, Srdan
    Ravandi, Farhad
    CLINICAL CANCER RESEARCH, 2013, 19 (02) : 327 - 335
12345